Last reviewed · How we verify
OMP-54F28
At a glance
| Generic name | OMP-54F28 |
|---|---|
| Sponsor | OncoMed Pharmaceuticals, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer (PHASE1)
- Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer (PHASE1)
- Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer (PHASE1)
- A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OMP-54F28 CI brief — competitive landscape report
- OMP-54F28 updates RSS · CI watch RSS
- OncoMed Pharmaceuticals, Inc. portfolio CI